Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib

Molecules

Volumn 11, Issue 4, 2006, Pages 286-297

  Knesl, Petr ^a   Röseling, Dirk ^a   Jordis, Ulrich ^a  

^a VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Quinazolines; Tyrosine kinase inhibitors

Indexed keywords

4 (6 METHOXY 7 (3 PIPERIDIN 1 YLPROPOXY)QUINAZOLIN 4 YL)PIPERAZINE 1 CARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 4-(6-METHOXY-7-(3-PIPERIDIN-1-YLPROPOXY)QUINAZOLIN-4-YL)PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXYPHENYL)AMIDE; ERLOTINIB; GEFITINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 33646430087     PISSN: 14203049     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/11040286     Document Type: Article

References (9)

1. Ciardiello, F.; De Vita, F.; Orditura, M.; De Placido, S.; Tortora, G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Exp. Opin. Emerg. Drugs 2003, 8, 501-514.
2. Pandey, A.; Volkots, D.L.; Seroogy, J.M.; Rose, J.W.; Yu, J.; Lambing, J.L.; Hutchaleelaha, A.; Hollenbach, S.J.; Abe, K.; Giese, N.A.; Scarborough, R.M. Identification of Orally Active, Potent, and Selective 4- Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family. J. Med. Chem. 2002, 45, 3772-3793.
3. Pandey, A.; Scarborough, R.M.; Matsuno, K.; Ichimura, M.; Nomoto, Y.; Fujiwara, S.; Ide, S.; Tsukuda, E.; Irie, J.; Oda, S. Preparation of 4-quinazolinyl-1-piperazinecarboxamides as kinase inhibitors for treatment of proliferative diseases. PCT Int. Appl. WO 2002016351, 2002.
4. Caponigro, F.; Ionna, F.; Comella, G. New cytotoxic and molecular-targeted therapies of head and neck tumors. Curr. Opin. Oncol. 2004, 16, 225-230.
5. Kelly, L.M.; Yu, J.C.; Boulton, C.L.; Apatira, M.; Li, J.; Sullivan, C.M.; Williams, I.; Amaral, S.M.; Curley, D.P.; Duclos, N.; Neuberg, D.; Scarborough, R.M.; Pandey, A.; Hollenbach, S.; Abe, K.; Lokker, N.A.; Gilliland, D.G.; Giese, N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1, 421-432.
6. Kanter, J.; Pandey, A.; Robinson, J.; Scarborough, R.M. Preparation of substituted piperazinoquinazolines as kinase inhibitors. PCT Int. Appl. WO 2002036587, 2002.
7. Springer, R.H.; Scholten, M.B.; O'Brien, D.E.; Novinson, T.; Miller, J.P.; Robins, R.K. Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3′,5′-phosphate phosphodiesterase inhibitor. J. Med. Chem. 1982, 25, 235-242.
8. Schnur, R.C.; Arnold, L.D. Preparation of alkynyl- and azido-substituted 4-anilinoquinazolines for the treatment of hyperproliferative diseases. US 5747498, 1998.
9. Gibson H.K. Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors. PCT Int. Appl. WO 9633980, 1996.